US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for a variety of diseases, including in the therapeutic areas of oncology, immunology, fibrosis, and neurology. Peter Schultz – CEO of Scripps Research and Calibr, its drug discovery unit, said: “Based […]
Continue reading …
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition news. Based in California, Audentes Therapeutics calls itself a clinical-stage company focused on developing a portfolio of Adeno-associated virus (AAV)-based genetic medicines for the […]
Continue reading …Global Blood Therapeutics bags Oxbryta FDA approval for sickle cell disease
November 27, 2019 No Comment
Oxbryta FDA approval : Global Blood Therapeutics (GBT), a California-based biopharma company, has bagged approval for Oxbryta (voxelotor) tablets from the US Food and Drug Administration (FDA) for sickle cell disease (SCD). The FDA approval of Oxbryta is for the treatment of adults and children, aged 12 years of age and older, who are suffering […]
Continue reading …
Mynosys Cellular Devices, which manufactures the Zepto cataract surgery device, has secured $25 million in a funding round led by investment firm Decheng Capital. The California-based ophthalmic technology company intends to use the funds to accelerate its growth in the US market and also to build a strong and sustainable R&D, manufacturing and commercial organization. […]
Continue reading …
Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor beta agonist VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The California-based biopharma company said that clinical trial sites have been opened for enrolling patients after it got clearance of investigational new drug (IND) application for the NASH […]
Continue reading …
Merck acquisition of Calporta : Merck has acquired Calporta Therapeutics from COI Pharmaceuticals in a deal worth up to $576 million, as per the latest pharma acquisition news. Calporta Therapeutics, which was launched in early 2015, is engaged in the development of selective small-molecule agonists to TRPML1. According to COI Pharmaceuticals, TRPML1 is thought to […]
Continue reading …
EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of small molecule immunotherapy and its oncolytic viral platform. The oncology company used the services of Biotech Alliances International, a Silicon Valley based life-science focused investment bank to get the funding. […]
Continue reading …Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome
October 29, 2019 No Comment
Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA) for the treatment of pruritus associated with Alagille syndrome (ALGS) in patients, aged 1 year and older. The California-based biopharma company is engaged in the development and commercialization of new therapies for debilitating liver diseases. Alagille syndrome […]
Continue reading …DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial
October 15, 2019 No Comment
Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate, in wet age-related macular degeneration (wet AMD). The DAZZLE trial (also called KSI-CL-102) is designed to assess the safety and efficacy of KSI-301 in AMD patients who are treatment-naïve. […]
Continue reading …
Agilent acquisition of BioTek : US-based lab instrument manufacturer Agilent Technologies has wrapped up its previously announced $1.16 billion acquisition of life science instrumentation manufacturer BioTek Instruments. The acquisition, which was announced in July 2019, is expected to boost Agilent’s position in the growing cell analysis segment. It was in 2015 when Agilent forayed into […]
Continue reading …
Business News Today
- ABG buys majority stake in spirits distribution company Indie Brands
- Arthur J. Gallagher acquires Illinois-based Affiliated Benefit Consultants
- Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer
- Antios Therapeutics begins phase 1 trial for ATI-2173, a chronic hepatitis B candidate
- Wings Financial to acquire Minnesota-based Neighborhood National Bank
- Greater Tortue Ahmeyim project : Kosmos Energy signs SPA with BP Gas Marketing
- ConocoPhillips hits dry well in PL 917 near Balder field in North Sea
- Icahn Automotive acquires automotive service chain Tecnicentros Mundial
- Australian clinical diagnostics company SpeeDx raises $15m in Series B round
- PCI acquires Canadian pharma packaging company Bellwyck Pharma Services
